ASLN
ASLAN PharmaceuticalsASLN
ASLN
Delisted
ASLN was delisted on the 19th of July, 2024.
About: ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment.
Employees: 35
Financial journalist opinion
Charts implemented using Lightweight Charts™